Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.1 (
ERK
)
95,504
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The accumulation of apoptotic cells is one of the pathological characteristics of systemic lupus erythematosus (SLE). The expression of
urokinase-type plasminogen activator receptor
(
uPAR
) has been reported to be increased in SLE patients and to be involved in macrophage efferocytosis. Although the toll-like receptor 7 (TLR7) is also over-expressed in lupus, its relationship to
uPAR
and its role in macrophage efferocytosis in lupus is still unclear. In the present study, we revealed that apoptotic cells accumulate in the spleen, macrophage efferocytosis is impaired, and
uPAR
is increased in the spleen and peritoneal macrophages of the TLR7 agonist imiquimod (IMQ)-induced SLE mouse model. Moreover, TLR7 upregulated
uPAR
expression in the mouse macrophage RAW 264.7 cells in vitro. The same results were also obtained using peritoneal macrophages of female Balb/c mice. When
uPAR
levels in peritoneal macrophages were knocked down by siRNA or inhibited by the peptide inhibitor UPARANT, and cells further treated with the TLR7 agonist R848, efferocytosis of peritoneal macrophages on apoptotic cells was restored. These results indicated that TLR7 activation impaired efferocytosis via
uPAR
in mouse peritoneal macrophages. Furthermore, TLR7 regulated
uPAR
expression via
ERK
/JNK signaling in macrophages. These results suggest that
uPAR
may be an important factor related to the accumulation of apoptotic cells in SLE.
...
PMID:Urokinase-type plasminogen activator receptor is required for impairing toll-like receptor 7 signaling on macrophage efferocytosis in lupus. 3291 23
Exosomes (Exos) have been reported to promote pre-metastatic niche formation, proliferation, angiogenesis and metastasis. We have investigated the role of
uPAR
in melanoma cell lines-derived Exos and their pro-angiogenic effects on human microvascular endothelial cells (HMVECs) and endothelial colony-forming cells (ECFCs). Melanoma Exos were isolated from conditioned media of A375 and M6 cells by differential centrifugation and filtration. Tunable Resistive Pulse Sensing (TRPS) and Nanoparticle tracking analysis were performed to analyze dimension and concentration of Exos. The CRISPR-Cas 9 technology was exploited to obtain a robust
uPAR
knockout.
uPAR
is expressed in melanoma Exos that are internalized by HMVECs and ECFCs, enhancing VE-Cadherin,
EGFR
and
uPAR
expression in endothelial cells that undergo a complete angiogenic program, including proliferation, migration and tube formation.
uPAR
loss reduced the pro-angiogenic effects of melanoma Exos in vitro and in vivo by inhibition of VE-Cadherin,
EGFR
and
uPAR
expression and of ERK1,2 signaling in endothelial cells. A similar effect was obtained with a peptide that inhibits
uPAR
-
EGFR
interaction and with the
EGFR
inhibitor Gefitinib, which also inhibited melanoma Exos-dependent
EGFR
phosphorylation. This study suggests that
uPAR
is required for the pro-angiogenic activity of melanoma Exos. We propose the identification of
uPAR
-expressing Exos as a potentially useful biomarker for assessing pro-angiogenic propensity and eventually monitoring the response to treatment in metastatic melanoma patients.
...
PMID:uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells. 3323 52
<< Previous
1
2
3
4
5
6
7
8
9
10